中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 11
Nov.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(11): 2258-2264

High-risk factors for significant liver histopathological damage in patients with indeterminate phase of chronic HBV infection

DOI: 10.12449/JCH251110
  • 1.

    Chinese PLA Medical School，Beijing 100853，China

  • 2.

    Senior Department of Hepatology，The Fifth Medical Center of Chinese PLA General Hospital，Beijing 100039，China

  • 3.

    Department of Anti-Nuclear，Biological and Chemical Medicine，Chinese PLA General Hospital，Beijing 100853，China

  • 4.

    Peking University 302 Clinical Medical School，Beijing 100039，China

Research funding:

National Key Research and Development Program Project (2023YFC2306800);

National Natural Science Foundation of China (82470632)

More Information
  • Corresponding author: LIU Miao， liumiaolmbxb@163.com （ORCID： 0000-0002-7975-6702）; JI Dong， jidg302@126.com （ORCID： 0000-0001-8214-462X）
  • Received Date: 2025-04-22
  • Accepted Date: 2025-07-11
  • Published Date: 2025-11-25
    Abstract
  •   Objective  To investigate the features of liver histopathological damage in patients with indeterminate phase of chronic HBV infection， as well as the timing for initiating antiviral therapy in such patients.  Methods  A retrospective screening was performed for the patients with chronic HBV infection who were hospitalized in The Fifth Medical Center of Chinese PLA General Hospital and underwent liver biopsy from March 2018 to April 2022， among whom the patients who met the criteria for indeterminate phase defined in Chinese guidelines for chronic hepatitis B prevention and treatment （2022 edition） were enrolled， and their clinical data were collected. Liver histopathological stage was determined using the Scheuer scoring system， with stages 0 — 4 for inflammation grade （G） and stages 0 — 4 for fibrosis degree （S）， and the patients were divided into groups based on the presence of significant necroinflammation （≥G2） and significant liver fibrosis （≥S2）. The independent samples t-test was used for comparison of normally distributed continuous data between two groups， and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups； the chi-square test or the Fisher’s exact test was used for comparison of categorical data between two groups. A Spearman’s rank correlation analysis was used to investigate the correlation between liver histopathology and clinical factors， and the Logistic regression model was used to identify the independent influencing factors for significant necroinflammation and liver fibrosis.  Results  A total of 271 patients with indeterminate phase of chronic HBV infection were enrolled， among whom 61 （22.5%） had significant necroinflammation （≥G2） and 124 （45.8%） had significant liver fibrosis （≥S2）. The Logistic regression analysis showed that alanine aminotransferase ≥30 U/L （for male patients） or ≥19 U/L （for female patients） （odds ratio ［OR］=2.69， 95% confidence interval ［CI］： 1.39 — 5.21， P=0.003）， HBV DNA ≥2 000 IU/mL （OR=2.75， 95%CI： 1.38 — 5.48， P=0.004）， and liver stiffness measurement （LSM） ≥6.0 kPa （OR=4.57， 95%CI： 2.17 — 9.62， P<0.001） were independent risk factors for significant inflammation. HBV DNA ≥2 000 IU/mL （OR=1.82， 95%CI： 1.01 — 3.32， P=0.049） and LSM ≥6.0 kPa （OR=2.06， 95%CI： 1.23 — 3.43， P=0.006） were independent influencing factors for significant liver fibrosis.  Conclusion  Among the patients with indeterminate phase of chronic HBV infection， a substantial proportion of patients have significant liver histopathological damage. Antiviral therapy should be initiated in a timely manner for patients with high-risk factors.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    JENG WJ, PAPATHEODORIDIS GV, LOK ASF. Hepatitis B[J]. Lancet, 2023, 401( 10381): 1039- 1052. DOI: 10.1016/S0140-6736(22)01468-4.
    [2]
    HUI CK, LEUNG N, YUEN ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase[J]. Hepatology, 2007, 46( 2): 395- 401. DOI: 10.1002/hep.21724.
    [3]
    European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67( 2): 370- 398. DOI: 10.1016/j.jhep.2017.03.021.
    [4]
    WANG CY, YANG WC, TAN WH, et al. Value of a nomogram model in predicting significant liver injury in patients with immune-tolerant phase chronic hepatitis B[J]. J Clin Hepatol, 2021, 37( 7): 1529- 1533. DOI: 10.3969/j.issn.1001-5256.2021.07.010.

    王春艳, 杨武才, 谭文辉, 等. 慢性乙型肝炎免疫耐受期患者显著肝损伤的列线图模型及其预测价值分析[J]. 临床肝胆病杂志, 2021, 37( 7): 1529- 1533. DOI: 10.3969/j.issn.1001-5256.2021.07.010.
    [5]
    GAN QY, WANG JX, QIAN F, et al. Clinical and histological features of patients with chronic hepatitis B virus infection in the grey zone[J]. J Viral Hepat, 2023, 30( 10): 803- 809. DOI: 10.1111/jvh.13873.
    [6]
    ZHUANG H. Further discussion on the antiviral treatment of chronic hepatitis B patients with indeterminate phase[J]. J Clin Hepatol, 2023, 39( 10): 2273- 2276. DOI: 10.3969/j.issn.1001-5256.2023.10.001.

    庄辉. 不确定期慢性乙型肝炎抗病毒治疗再探讨[J]. 临床肝胆病杂志, 2023, 39( 10): 2273- 2276. DOI: 10.3969/j.issn.1001-5256.2023.10.001.
    [7]
    BRAVO AA, SHETH SG, CHOPRA S. Liver biopsy[J]. N Engl J Med, 2001, 344( 7): 495- 500. DOI: 10.1056/nejm200102153440706.
    [8]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B[J]. Infect Dis Info, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 传染病信息, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.
    [9]
    WONG GL, LEMOINE M. The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: Main changes and potential implications for the next major liver society clinical practice guidelines[J]. J Hepatol, 2025, 82( 5): 918- 925. DOI: 10.1016/j.jhep.2024.12.004.
    [10]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis(2019)[J]. J Clin Hepatol, 2019, 35( 10): 2163- 2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年)[J]. 临床肝胆病杂志, 2019, 35( 10): 2163- 2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.
    [11]
    Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update[J]. J Clin Hepatol, 2015, 31( 12): 1941- 1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31( 12): 1941- 1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.
    [12]
    Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Disease and Chinese Society of Hepatology, Chinese Medical Association; Liver Disease Committee of Chinese Research Hospital Association. Consensus on clinical application of transient elastography detecting liver fibrosis: A 2018 update[J]. Chin J Hepatol, 2019, 27( 3): 182- 191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.

    中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会和中国研究型医院学会肝病专业委员会. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]. 中华肝脏病杂志, 2019, 27( 3): 182- 191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.
    [13]
    WANG H, RU GQ, YAN R, et al. Histologic disease in Chinese chronic hepatitis B patients with low viral loads and persistently normal alanine aminotransferase levels[J]. J Clin Gastroenterol, 2016, 50( 9): 790- 796. DOI: 10.1097/mcg.0000000000000544.
    [14]
    DUAN MH, CHI XL, XIAO HM, et al. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B[J]. Hepatol Int, 2021, 15( 2): 318- 327. DOI: 10.1007/s12072-021-10153-2.
    [15]
    HUANG DQ, TRAN A, YEH ML, et al. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase[J]. Hepatology, 2023, 78( 5): 1558- 1568. DOI: 10.1097/hep.0000000000000459.
    [16]
    ZENG Z, HAO HX, BI XY, et al. Study on liver histopathology of chronic HBV infected patients with different normal ALT values[J]. Front Immunol, 2022, 13: 1069752. DOI: 10.3389/fimmu.2022.1069752.
    [17]
    SONNEVELD MJ, BROUWER WP, HANSEN BE, et al. Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis[J]. Aliment Pharmacol Ther, 2020, 52( 8): 1399- 1406. DOI: 10.1111/apt.16067.
    [18]
    JUNG KS, KIM SU, AHN SH, et al. Risk assessment of hepatitis B virus–related hepatocellular carcinoma development using liver stiffness measurement(FibroScan)[J]. Hepatology, 2011, 53( 3): 885- 894. DOI: 10.1002/hep.24121.
    [19]
    TAN YW, YE Y, ZHOU XB, et al. Age as a predictor of significant fibrosis features in HBeAg-negative chronic hepatitis B virus infection with persistently normal alanine aminotransferase[J]. PLoS One, 2015, 10( 4): e0123452. DOI: 10.1371/journal.pone.0123452.
    [20]
    XU Y, LIU H, WANG Y, et al. The next step in controlling HBV in China[J]. BMJ, 2013, 347(jul16 1): f4503. DOI: 10.1136/bmj.f4503.
    [21]
    INDOLFI G, EASTERBROOK P, DUSHEIKO G, et al. Hepatitis B virus infection in children and adolescents[J]. Lancet Gastroenterol Hepatol, 2019, 4( 6): 466- 476. DOI: 10.1016/S2468-1253(19)30042-1.
    [22]
    LIAW YF, LAU GKK, KAO JH, et al. Hepatitis B e antigen seroconversion: A critical event in chronic hepatitis B virus infection[J]. Dig Dis Sci, 2010, 55( 10): 2727- 2734. DOI: 10.1007/s10620-010-1179-4.
    [23]
    ISOGAWA M, TANAKA Y. Immunobiology of hepatitis B virus infection[J]. Hepatol Res, 2015, 45( 2): 179- 189. DOI: 10.1111/hepr.12439.
    [24]
    WANG SH, CHEN PJ, YEH SH. Gender disparity in chronic hepatitis B: Mechanisms of sex hormones[J]. J Gastroenterol Hepatol, 2015, 30( 8): 1237- 1245. DOI: 10.1111/jgh.12934.
    [25]
    WU JF, SONG SH, LEE CS, et al. Clinical predictors of liver fibrosis in patients with chronic hepatitis B virus infection from children to adults[J]. J Infect Dis, 2018, 217( 9): 1408- 1416. DOI: 10.1093/infdis/jiy048.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (7) PDF downloads(4) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return